FDA approves Merck rotavirus vaccine

Share this article:
The FDA has approved Merck’s RotaTeq (rotavirus vaccine, live, oral, pentavalent) to prevent rotavirus gastroenteritis, a leading cause of severe diarrhea in infants and young children that kills nearly 500,000 children globally each year. Analysts forecast the vaccine could bring Merck as much as $500 million annually by 2009. RotaTeq is the second vaccine for rotavirus to be put on the market. The first, Wyeth’s RotaSheild, was withdrawn just 10 months after it debuted in September 1998.  The drug maker could start fielding orders from doctors immediately and would be able to ship doses as early as this week.
Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.